Biosynthetic Neoantigen Displayed on Bacteria Derived Vesicles Elicit Systemic Antitumour Immunity

Overview

Journal J Extracell Vesicles

Publisher Wiley

Date 2022 Dec 5

PMID 36468941

Authors

Fanqiang Meng

Liyan Li

Zhirang Zhang

Zhongda Lin

Jinxie Zhang

Xiao Song

Tianyuan Xue

Chenyang Xing

Xin Liang

Xudong Zhang

Affiliations

Soon will be listed here.

Abstract

Neoantigens derived from mutant proteins in tumour cells could elicit potent personalized anti-tumour immunity. Nevertheless, the layout of vaccine vehicle and synthesis of neoantigen are pivotal for stimulating robust response. The power of synthetic biology enables genetic programming bacteria to produce therapeutic agents under contol of the gene circuits. Herein, we genetically engineered bacteria to synthesize fusion neoantigens, and prepared bacteria derived vesicles (BDVs) presenting the neoantigens (BDVs-Neo) as personalized therapeutic vaccine to drive systemic antitumour response. BDVs-Neo and granulocyte-macrophage colony-stimulating factor (GM-CSF) were inoculated subcutaneously within hydrogel (Gel), whereas sustaining release of BDVs-Lipopolysaccharide (LPS) and GM-CSF recruited the dendritic cells (DCs). Virtually, Gel-BDVs-Neo combined with the programmed cell death protein 1 (PD-1) antibody intensively enhanced proliferation and activation of tumour-infiltrated T cells, as well as memory T cell clone expansion. Consequently, BDVs-Neo combining with checkpoint blockade therapy effectively prevented tumour relapse and metastasis.

Citing Articles

Exosomes, their sources, and possible uses in cancer therapy in the era of personalized medicine.

Zemanek T, Danisovic L, Nicodemou A J Cancer Res Clin Oncol. 2024; 151(1):16.

PMID: 39724442 PMC: 11671574. DOI: 10.1007/s00432-024-06066-w.

Protecting Against Postsurgery Oral Cancer Recurrence with an Implantable Hydrogel Vaccine for In Situ Photoimmunotherapy.

Chen L, Yin Q, Zhang H, Zhang J, Yang G, Weng L Adv Sci (Weinh). 2024; 11(46):e2309053.

PMID: 39467056 PMC: 11633475. DOI: 10.1002/advs.202309053.

Oral administration of Sophora Flavescens-derived exosomes-like nanovesicles carrying CX5461 ameliorates DSS-induced colitis in mice.

Zhang M, Xu X, Su L, Zeng Y, Lin J, Li W J Nanobiotechnology. 2024; 22(1):607.

PMID: 39379937 PMC: 11463058. DOI: 10.1186/s12951-024-02856-z.

Photosynthetic bacteria-based whole-cell inorganic-biohybrid system for multimodal enhanced tumor radiotherapy.

Hua S, Zhao J, Li L, Liu C, Zhou L, Li K J Nanobiotechnology. 2024; 22(1):379.

PMID: 38943158 PMC: 11212166. DOI: 10.1186/s12951-024-02654-7.

Interaction between intestinal flora and gastric cancer in tumor microenvironment.

Yang M Front Oncol. 2024; 14:1402483.

PMID: 38835386 PMC: 11148328. DOI: 10.3389/fonc.2024.1402483.

References

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Keskin D, Anandappa A, Sun J, Tirosh I, Mathewson N, Li S . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018; 565(7738):234-239. PMC: 6546179. DOI: 10.1038/s41586-018-0792-9. View

Farhood B, Najafi M, Mortezaee K . CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2018; 234(6):8509-8521. DOI: 10.1002/jcp.27782. View

Voskoboinik I, Whisstock J, Trapani J . Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015; 15(6):388-400. DOI: 10.1038/nri3839. View

Russell J, Ley T . Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002; 20:323-70. DOI: 10.1146/annurev.immunol.20.100201.131730. View

Meng F, Li L, Zhang Z, Lin Z, Zhang J, Song X . Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity. J Extracell Vesicles. 2022; 11(12):e12289. PMC: 9721206. DOI: 10.1002/jev2.12289. View

McNerney M, Doiron K, Ng T, Chang T, Silver P . Theranostic cells: emerging clinical applications of synthetic biology. Nat Rev Genet. 2021; 22(11):730-746. PMC: 8261392. DOI: 10.1038/s41576-021-00383-3. View

Huang W, Wang S, Yao Y, Xia Y, Yang X, Li K . Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci Rep. 2016; 6:37242. PMC: 5110958. DOI: 10.1038/srep37242. View

Cheng K, Zhao R, Li Y, Qi Y, Wang Y, Zhang Y . Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nat Commun. 2021; 12(1):2041. PMC: 8024398. DOI: 10.1038/s41467-021-22308-8. View

10.

Zanella I, Konig E, Tomasi M, Gagliardi A, Frattini L, Fantappie L . Proteome-minimized outer membrane vesicles from as a generalized vaccine platform. J Extracell Vesicles. 2021; 10(4):e12066. PMC: 7886703. DOI: 10.1002/jev2.12066. View

11.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

12.

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S . Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014; 11(9):509-24. DOI: 10.1038/nrclinonc.2014.111. View

13.

Kovacs-Simon A, Titball R, Michell S . Lipoproteins of bacterial pathogens. Infect Immun. 2010; 79(2):548-61. PMC: 3028857. DOI: 10.1128/IAI.00682-10. View

14.

McLane L, Abdel-Hakeem M, Wherry E . CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37:457-495. DOI: 10.1146/annurev-immunol-041015-055318. View

15.

Huang W, Zhang Q, Li W, Yuan M, Zhou J, Hua L . Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism. J Control Release. 2019; 317:1-22. DOI: 10.1016/j.jconrel.2019.11.017. View

16.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

17.

Li Y, Zhao R, Cheng K, Zhang K, Wang Y, Zhang Y . Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy Immune Activation and Checkpoint Inhibition. ACS Nano. 2020; 14(12):16698-16711. DOI: 10.1021/acsnano.0c03776. View

18.

Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D . Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019; 25(5):767-775. PMC: 6558662. DOI: 10.1038/s41591-019-0434-2. View

19.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

20.

Gurbatri C, Lia I, Vincent R, Coker C, Castro S, Treuting P . Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020; 12(530). PMC: 7685004. DOI: 10.1126/scitranslmed.aax0876. View